

# METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-3 RECEPTOR

---

## 1. FIELD OF INVENTION

5 The present invention relates generally to methods of inhibiting a biological activity mediated by the Edg-3 receptor. More specifically, the present invention provides compounds, which may be used to selectively inhibit the Edg-3 receptor. The present invention also provides methods for making these compounds and methods of using compositions, which may used to selectively inhibit the Edg-3 receptor.

10

## 2. BACKGROUND OF THE INVENTION

Recent studies have revealed a complex biological role for cell membrane phospholipids, which were previously believed to have only a structural function. Following cell activation, membrane phospholipids may be metabolized to eicosanoids and lysophospholipids, which are important regulators of cellular function and behavior. Lysophospholipids include compounds such as lysophosphatidic acid (15 "LPA"), sphingosine-1-phosphate ("S1P"), lysophosphatidylcholine and sphingosylphosphorylcholine and are important second messengers that can activate particular cell surface transmembrane G-protein coupled receptors known as endothelial gene differentiation ("Edg") receptors.

20

Currently, either LPA or S1P is known to activate eight Edg receptors while related lysophospholipids activate at least four others.

Edg-1, Edg-3, Edg-5, Edg-6 and Edg-8 receptors are activated by S1P, while LPA activates Edg-2, Edg-4 and Edg-7 receptors. Although, all three LPA receptors (i.e., Edg-2, Edg-4 and Edg-7) bind LPA, compounds, which discriminate between these receptors have been identified (Im *et al.*, 2000, *Mol. Pharmacol.* 57 (4):753-25 759).

Importantly, Edg receptors are believed to mediate critical cellular events such as cell proliferation and cell migration, which makes these receptors attractive therapeutic targets. However, currently known compounds, which bind to LPA, are almost exclusively phospholipids (*e.g.*, LPA and S1P, analogs of LPA and S1P, dioctyl glycerol, *etc.*). Most of these phospholipids compounds fail to effectively


30

discriminate between different Edg receptors and have poor physicochemical properties, which limits their potential use as pharmaceutical agents. Thus, there exists a need for compounds, which are not phospholipids that bind or otherwise regulate Edg receptors and can also selectively bind to a specific Edg receptor.

5

### 3. SUMMARY OF THE INVENTION

The present invention addresses these and other needs by providing inhibitors, which are not phospholipids that may be used to selectively bind or otherwise regulate the Edg-3 receptor. The present invention provides compounds (agonists or  
10 antagonists) that modulate Edg-2 receptor mediated biological activity. The agonists or antagonists are compounds of structural formula (I) and can be utilized as part of the methods of the present invention:



15


(I)

or a pharmaceutically available solvate or hydrate thereof, wherein;

each of  $R_1$ ,  $R_2$  and  $R_3$  is independently -H, -halo, -NO<sub>2</sub>, -CN, -C(R<sub>5</sub>)<sub>3</sub>, -(CH<sub>2</sub>)<sub>m</sub>OH,  
20 -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>,  
-benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl,  
-(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl,  
-(C<sub>6</sub>)heteroaryl, -(C<sub>5</sub>-C<sub>10</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>,  
-N(OH)aryl, -NHC(O)R<sub>5</sub>, -NHC(O)OR<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -heterocylcoalkyl,  
25 -C(S)N(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkylNHC(O)(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkylNR<sub>5</sub>R<sub>5</sub>,  
-OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>,  
-S(O)<sub>2</sub>NHR<sub>5</sub>, or



$R_3$  is  $-H$ ,  $-C(R_5)_3$ ,  $-(CH_2)_mOH$ ,  $-C(O)R_5$ ,  $-C(O)NR_5R_5$ ,  $-C(O)NH(CH_2)_m(R_5)$ ,  $-benzyl$ ,  
 $-CO_2CH(R_5)(R_5)$ ,  $-(C_1-C_{10})alkyl$ ,  $-(C_2-C_{10})alkenyl$ ,  $-(C_2-C_{10})alkynyl$ ,  
 $-(C_3-C_{10})cycloalkyl$ ,  $-(C_8-C_{14})bicycloalkyl$ ,  $-(C_5-C_{10})cycloalkenyl$ ,  $-(C_5)heteroaryl$ ,  
 $-(C_6)heteroaryl$ ,  $-(C_5-C_{10})heteroaryl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})heterocycle$ ,  $-CO_2(CH_2)_mR_5$ ,  
5  $-N(OH)aryl$ ,  $-NHC(O)R_5$ ,  $-NHC(O)OR_5$ ,  $-NHC(O)NHR_5$ ,  $-N=C(aryl)$ ,  
 $-heterocylcoalkyl$ ,  $-(C_1-C_{10})alkylNHC(O)(CH_2)_mR_5$ ,  $-(C_1-C_{10})alkylNR_5R_5$ ,  
 $-OC(O)(CH_2)_mCHR_5R_5$ ,  $-CO_2(CH_2)_mCHR_5R_5$ ,  $-OC(O)OR_5$ ,  $-SR_5$ ,  $-S(O)R_5$ ,  $-S(O)_2R_5$ ,  
 $-S(O)_2NHR_5$ , or



10

wherein;

each  $R_5$  and  $R_6$  is independently  $-H$ ,  $-halo$ ,  $-NO_2$ ,  $-CN$ ,  $-OH$ ,  $-CO_2H$ ,  
 $-N(C_1-C_{10})alkyl(C_1-C_{10})alkyl$ ,  $-O(C_1-C_{10})alkyl$ ,  $-C(O)(C_1-C_{10})alkyl$ ,  
 $-C(O)NH(CH_2)_m(C_1-C_{10})alkyl$ ,  $-OCF_3$ ,  $-benzyl$ ,  $-CO_2(CH_2)_mCH((C_1-C_{10})alkyl(C_1-$   
15  $C_{10})alkyl)$ ,  $-CO_2(C_1-C_{10})alkyl$ ,  $-(C_1-C_{10})alkyl$ ,  $-(C_2-C_{10})alkenyl$ ,  $-(C_2-C_{10})alkynyl$ ,  
 $-(C_3-C_{10})cycloalkyl$ ,  $-(C_8-C_{14})bicycloalkyl$ ,  $-(C_5-C_{10})cycloalkenyl$ ,  $-(C_5)heteroaryl$ ,  
 $-(C_6)heteroaryl$ ,  $-phenyl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})heterocycle$ ,  $-CO_2(CH_2)_m(C_1-C_{10})alkyl$ ,  
 $-CO_2(CH_2)_mH$ ,  $-NHC(O)(C_1-C_{10})alkyl$ ,  $-NHC(O)NH(C_1-C_{10})alkyl$ ,  $-NH(aryl)$ ,  
 $-N=C(aryl)$ ,  $-OC(O)O(C_1-C_{10})alkyl$ , or  $-SO_2NH_2$ ;

20  $X$  is  $O$ ,  $S$ , or  $N(R_5)$ ;

$R_1$ ,  $R_2$  or  $R_3$  taken in combination can form one or more substituted or  
 unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered aromatic  
 ring;

- two  $R_6$  groups on adjacent carbon atoms can together form a 5 or 6 membered  
 25 cyclic or heterocyclic ring or a 6-membered aromatic ring;

each  $m$  is independently an integer ranging from 0 to 8; and

each  $p$  is independently an integer ranging from 0 to 5.

These compounds may be more suitable for pharmaceutical development and  
 may have more specific pharmacological modes of action than currently known Edg  
 30 receptor ligands. The present invention provides methods for inhibiting Edg-3  
 receptor mediated biological activity The present invention also provides methods for

using Edg-3 modulators (agonists and antagonists) in treating or preventing diseases such as ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer; acute lung diseases, adult respiratory distress syndrome ("ARDS"), acute inflammatory exacerbation of chronic lung diseases such as asthma, surface epithelial cell injury, (*e.g.*, transcorneal freezing or cutaneous burns) and cardiovascular diseases (*e.g.*, ischemia) in a subject in need of such treatment or prevention. Further, the present invention provides compounds and compositions that can, for example, be used in modulating Edg-3 receptor mediated biological activity or treating or preventing diseases such as those mentioned above.

In one embodiment, the present invention provides a method of inhibiting an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with an amount of an Edg-3 receptor inhibitor sufficient to inhibit the Edg-3 receptor mediated biological activity. Preferably, the inhibitor is not a phospholipid.

In a second embodiment, the present invention provides a method where an Edg-3 receptor mediated biological activity is inhibited in a subject. A therapeutically effective amount of an inhibitor of the Edg-3 receptor is administered to the subject. Preferably, the inhibitor is not a phospholipid.

#### 4. DEFINITIONS

"Compounds of the invention" refers generally to any inhibitors of the Edg-3 receptor and includes any inhibitors of the Edg-3 receptor encompassed by generic formulae disclosed herein and includes any specific inhibitors within those formulae whose structure is disclosed herein. The compounds of the invention may be identified either by their chemical structure and/or chemical name. If the chemical structure and chemical name conflict, the chemical structure is determinative of the identity of the compound. The compounds of the invention may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (*i.e.*, geometric isomers), enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (*e.g.*, geometrically pure, enantiomerically pure or

diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds of the invention may also exist in several  
5 tautomeric forms including, but not limited to, the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. The compounds of the invention also include isotopically labeled where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of  
10 isotopes that may be incorporated in the compounds of the invention include, but are not limited to,  $^2\text{H}$ ,  $^3\text{H}$ ,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{31}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{18}\text{F}$ , and  $^{36}\text{Cl}$ . Further, it should be understood that when partial structures of the compounds of the invention are illustrated, brackets indicate the point of attachment of the partial structure to the rest of the compound.

15

“Composition of the invention” refers to at least one compound of the invention and a pharmaceutically acceptable vehicle, with which the compound is administered to a patient. When administered to a patient, the compounds of the invention are administered in isolated form, which means separated from a synthetic  
20 organic reaction mixture.

“Alkyl” refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include,  
25 but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl,  
30 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like.

The term “alkyl” is specifically intended to include groups having any degree or level of saturation, *i.e.*, groups having exclusively single carbon-carbon bonds,

groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds and groups having mixtures of single, double and triple carbon-carbon bonds. Where a specific level of saturation is intended, the expressions “alkanyl,” “alkenyl,” and “alkynyl” are used. Preferably, an alkyl group comprises  
5 from 1 to 20 carbon atoms.

“Alkanyl” refers to a saturated branched, straight-chain or cyclic alkyl group derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl;  
10 propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such as butan-1-yl, butan-2-yl (*sec*-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (*t*-butyl), cyclobutan-1-yl, *etc.*; and the like.

“Alkenyl” refers to an unsaturated branched, straight-chain or cyclic alkyl  
15 group having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The group may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl;  
20 cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, *etc.*; and the like.

25 “Alkynyl” refers to an unsaturated branched, straight-chain or cyclic alkyl group having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl,  
30 *etc.*; and the like.

“Acyl” refers to a radical -C(O)R, where R is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl as defined

herein. Representative examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

5       “Acylamino” refers to a radical  $-NR'C(O)R$ , where  $R'$  and  $R$  are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein. Representative examples include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino, benzylcarbonylamino and the like.

10       “Alkylamino” means a radical  $-NHR$  where  $R$  represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylamino, ethylamino, 1-methylethylamino, cyclohexyl amino and the like.

15       “Alkoxy” refers to a radical  $-OR$  where  $R$  represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclohexyloxy and the like.

20       “Alkoxy carbonyl” refers to a radical  $-C(O)-alkoxy$  where alkoxy is as defined herein.

      “Alkylaryl amino” refers to a radical  $-NRR'$  where  $R$  represents an alkyl or cycloalkyl group and  $R'$  is an aryl as defined herein

25       “Alkylsulfonyl” refers to a radical  $-S(O)_2R$  where  $R$  is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like.

30       “Alkylsulfinyl” refers to a radical  $-S(O)R$  where  $R$  is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl and the like.

      “Alkylthio” refers to a radical  $-SR$  where  $R$  is an alkyl or cycloalkyl group as defined herein that may be optionally substituted as defined herein. Representative

examples include, but are not limited to methylthio, ethylthio, propylthio, butylthio, and the like.

“Amino” refers to the radical -NH<sub>2</sub>.

5

“Aryl” refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. Preferably, an aryl group comprises from 6 to 20 carbon atoms.

15

“Arylalkyl” refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or *sp*<sup>3</sup> carbon atom, is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. Preferably, an arylalkyl group is (C<sub>6</sub>-C<sub>30</sub>) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C<sub>1</sub>-C<sub>10</sub>) and the aryl moiety is (C<sub>6</sub>-C<sub>20</sub>).

25

“Arylalkyloxy” refers to an -O-arylalkyl radical where arylalkyl is as defined herein.

30

“Arylamino” means a radical -NHR where R represents an aryl group as defined herein.

“Aryloxycarbonyl” refers to a radical -C(O)-O-aryl where aryl is as defined herein.



“Azido” refers to the radical  $-N_3$ .

5 “Carbamoyl” refers to the radical  $-C(O)N(R)_2$  where each R group is independently hydrogen, alkyl, cycloalkyl or aryl as defined herein, which may be optionally substituted as defined herein.

“Carboxy” means the radical  $-C(O)OH$ .

10 “Cyanato” means the radical  $-OCN$ .

“Cyano” means the radical  $-CN$ .

15 “Cycloalkyl” refers to a saturated or unsaturated cyclic alkyl group. Where a specific level of saturation is intended, the nomenclature “cycloalkanyl” or “cycloalkenyl” is used. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. In a preferred embodiment, the cycloalkyl group is  $(C_3-C_{10})$  cycloalkyl, more preferably  $(C_3-C_6)$  cycloalkyl.

20 “Cycloheteroalkyl” refers to a saturated or unsaturated cyclic alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom. Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, Si, *etc.* Where a  
25 specific level of saturation is intended, the nomenclature “cycloheteroalkanyl” or “cycloheteroalkenyl” is used. Typical cycloheteroalkyl groups include, but are not limited to, groups derived from epoxides, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like.

30 “Cycloheteroalkyloxycarbonyl” refers to a radical  $-C(O)-OR$  where R is cycloheteroalkyl as defined herein.

“Dialkylamino” means a radical  $-NRR'$  where R and R' independently represent an alkyl or cycloalkyl group as defined herein. Representative examples

include, but are not limited to dimethylamino, methylethylamino, di-(1-methylethyl)amino, (cyclohexyl)(methyl)amino, (cyclohexyl)(ethyl)amino, (cyclohexyl)(propyl)amino, and the like.

5           “Halo” means fluoro, chloro, bromo, or iodo.

          “Haloalkyl” means an alkyl radical substituted by one or more halo atoms wherein alkyl and halo is as defined herein.

10           “Heteroalkyloxy” means an -O-heteroalkyl group where heteroalkyl is as defined herein.

          “Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkynyl” refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon  
15 atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic groups. Typical heteroatomic groups include, but are not limited to, -O-, -S-, -O-O-, -S-S-, -O-S-, -NR'-, =N-N=, -N=N-, -N=N-NR'-, -PH-, -P(O)<sub>2</sub>-, -O-P(O)<sub>2</sub>-, -S(O)-, -S(O)<sub>2</sub>-, -SnH<sub>2</sub>- and the like, wherein R' is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl or substituted aryl.

20           “Heteroaryl” refers to a monovalent heteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole,  $\beta$ -carboline, chromane, chromene, cinnoline, furan,  
25 imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole,  
30 thiazole, thiophene, triazole, xanthene, and the like. Preferably, the heteroaryl group is between 5-20 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred. Preferred heteroaryl groups are those derived from thiophene,

pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.

5       “Heteroarylloxy” refers to an -O-heteroarylalkyl radical where heteroarylalkyl is as defined herein.

      “Heteroarylloxycarbonyl” refers to a radical -C(O)-OR where R is heteroaryl as defined herein.

10       “Heteroarylalkyl” refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or  $sp^3$  carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl and/or heteroarylalkynyl is used. In preferred embodiments, the heteroarylalkyl group is a 6-30 membered  
15 heteroarylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-10 membered and the heteroaryl moiety is a 5-20 membered heteroaryl.

      “Hydroxy” means the radical -OH.

20       “Leaving group” has the meaning conventionally associated with it in synthetic organic chemistry, *i.e.*, an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkoxycarbonyl (*e.g.*, acetoxo), aryloxycarbonyl, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (*e.g.*, 2,4-dinitrophenoxy), methoxy, N,O-dimethylhydroxylamino, and the  
25 like.

      “Nitro” means the radical -NO<sub>2</sub>.

      “Oxo” means the divalent radical =O.

30       “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like.

20

“Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.

“Patient” includes humans. The terms “human” and “patient” are used interchangeably herein.

25

“Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (*i.e.*, causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).

30

“Prodrug” refers to a pharmacologically inactive derivative of a drug molecule that requires a transformation within the body to release the active drug. Typically, prodrugs are designed to overcome pharmaceutical and/or pharmacokinetically based

problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.

5       “Promoiety” refers to a form of protecting group that when used to mask a functional group within a drug molecule converts the drug into a prodrug. Typically, the promoiety will be attached to the drug *via* bond(s) that are cleaved by enzymatic or non-enzymatic means *in vivo*. Ideally, the promoiety is rapidly cleared from the body upon cleavage from the prodrug.

10       “Protecting group” refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green *et al.*, “Protective Groups in Organic Chemistry”, (Wiley, 2<sup>nd</sup> ed. 1991) and Harrison *et al.*, “Compendium of Synthetic Organic Methods”, Vols. 1-8 (John Wiley and Sons, 1971-1996). Representative  
15       amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), *tert*-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilyl-ethanesulfonyl (“SES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“Fmoc”), nitro-  
20       veratryloxycarbonyl (“NVOC”) and the like. Representative hydroxy protecting groups include, but are not limited to, those where the hydroxy group is either acylated or alkylated such as benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.

      “Substituted” refers to a group in which one or more hydrogen atoms are each  
25       independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, -X, -R<sub>14</sub>, -O<sup>-</sup>, =O, -OR<sub>14</sub>, -SR<sub>14</sub>, -S<sup>-</sup>, =S, -NR<sub>14</sub>R<sub>15</sub>, =NR<sub>14</sub>, -CX<sub>3</sub>, -CF<sub>3</sub>, -CN, -OCN, -SCN, -NO, -NO<sub>2</sub>, =N<sub>2</sub>, -N<sub>3</sub>, -S(O)<sub>2</sub>O<sup>-</sup>, -S(O)<sub>2</sub>OH, -S(O)<sub>2</sub>R<sub>14</sub>, -OS(O<sub>2</sub>)O<sup>-</sup>, -OS(O)<sub>2</sub>R<sub>14</sub>, -P(O)(O<sup>-</sup>)<sub>2</sub>, -P(O)(OR<sub>14</sub>)(O<sup>-</sup>), -OP(O)(OR<sub>14</sub>)(OR<sub>15</sub>), -C(O)R<sub>14</sub>, -C(S)R<sub>14</sub>, -C(O)OR<sub>14</sub>, -C(O)NR<sub>14</sub>R<sub>15</sub>, -C(O)O<sup>-</sup>, -C(S)OR<sub>14</sub>, -  
30       NR<sub>16</sub>C(O)NR<sub>14</sub>R<sub>15</sub>, -NR<sub>16</sub>C(S)NR<sub>14</sub>R<sub>15</sub>, -NR<sub>17</sub>C(NR<sub>16</sub>)NR<sub>14</sub>R<sub>15</sub> and -C(NR<sub>16</sub>)NR<sub>14</sub>R<sub>15</sub>, where each X is independently a halogen; each R<sub>14</sub>, R<sub>15</sub>, R<sub>16</sub> and R<sub>17</sub> are independently hydrogen, alkyl, substituted alkyl, aryl, substituted alkyl, arylalkyl, substituted alkyl, cycloalkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted

heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, -NR<sub>18</sub>R<sub>19</sub>, -C(O)R<sub>18</sub> or -S(O)<sub>2</sub>R<sub>18</sub> or optionally R<sub>18</sub> and R<sub>19</sub> together with the atom to which they are both attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and R<sub>18</sub> and R<sub>19</sub> are independently hydrogen, alkyl, substituted alkyl, aryl, substituted alkyl, arylalkyl, substituted alkyl, cycloalkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

“Sulfonylamino” refers to a radical -NR’S(O<sub>2</sub>)R, where R’ and R are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein.

“Therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, *etc.*, of the patient to be treated.

“Thio” means the radical -SH.

“Thiocyanato” means the radical -SCN.

“Thiono” means the divalent radical =S.

“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (*i.e.*, arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet another embodiment, “treating” or “treatment” refers to inhibiting the disease or disorder, either physically, (*e.g.*, stabilization of a discernible symptom), physiologically, (*e.g.*, stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.


Reference will now be made in detail to preferred embodiments of the invention. While the invention will be described in conjunction with the preferred embodiments, it will be understood that it is not intended to limit the invention to those preferred embodiments. To the contrary, it is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims.

## 5. DETAILED DESCRIPTION OF THE INVENTION

### 10 5.1. The Use of the Compounds of the Invention


The present invention provides a method of modulating an Edg-3 receptor (e.g., human Edg-2, GenBank Accession No., X83864) mediated biological activity. A cell expressing the Edg-3 receptor is contacted with an amount of an Edg-3 receptor agonist or antagonist sufficient to modulate the Edg-3 receptor mediated biological activity.

The Edg-3 modulator has the structural formula (I):



20 or a pharmaceutically available solvate or hydrate thereof, wherein;

each of  $R_1$ ,  $R_2$  and  $R_3$  is independently -H, -halo, -NO<sub>2</sub>, -CN, -C(R<sub>5</sub>)<sub>3</sub>, -(CH<sub>2</sub>)<sub>m</sub>OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl, -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl, -(C<sub>6</sub>)heteroaryl, -(C<sub>5</sub>-C<sub>10</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -N(OH)aryl, -NHC(O)R<sub>5</sub>, -NHC(O)OR<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -heterocylcoalkyl, -C(S)N(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkylNHC(O)(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkylNR<sub>5</sub>R<sub>5</sub>, -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>, -S(O)<sub>2</sub>NHR<sub>5</sub>, or



- $R_3$  is  $-H$ ,  $-C(R_5)_3$ ,  $-(CH_2)_mOH$ ,  $-C(O)R_5$ ,  $-C(O)NR_5R_5$ ,  $-C(O)NH(CH_2)_m(R_5)$ ,  $-benzyl$ ,  
 $-CO_2CH(R_5)(R_5)$ ,  $-(C_1-C_{10})alkyl$ ,  $-(C_2-C_{10})alkenyl$ ,  $-(C_2-C_{10})alkynyl$ ,  
 $-(C_3-C_{10})cycloalkyl$ ,  $-(C_8-C_{14})bicycloalkyl$ ,  $-(C_5-C_{10})cycloalkenyl$ ,  $-(C_5)heteroaryl$ ,  
 5  $-(C_6)heteroaryl$ ,  $-(C_5-C_{10})heteroaryl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})heterocycle$ ,  $-CO_2(CH_2)_mR_5$ ,  
 $-N(OH)aryl$ ,  $-NHC(O)R_5$ ,  $-NHC(O)OR_5$ ,  $-NHC(O)NHR_5$ ,  $-N=C(aryl)$ ,  
 $-heterocylcoalkyl$ ,  $-(C_1-C_{10})alkylNHC(O)(CH_2)_mR_5$ ,  $-(C_1-C_{10})alkylNR_5R_5$ ,  
 $-OC(O)(CH_2)_mCHR_5R_5$ ,  $-CO_2(CH_2)_mCHR_5R_5$ ,  $-OC(O)OR_5$ ,  $-SR_5$ ,  $-S(O)R_5$ ,  $-S(O)_2R_5$ ,  
 $-S(O)_2NHR_5$ , or

10



wherein;

- each  $R_5$  and  $R_6$  is independently  $-H$ ,  $-halo$ ,  $-NO_2$ ,  $-CN$ ,  $-OH$ ,  $-CO_2H$ ,  
 $-N(C_1-C_{10})alkyl(C_1-C_{10})alkyl$ ,  $-O(C_1-C_{10})alkyl$ ,  $-C(O)(C_1-C_{10})alkyl$ ,  
 15  $-C(O)NH(CH_2)_m(C_1-C_{10})alkyl$ ,  $-OCF_3$ ,  $-benzyl$ ,  $-CO_2(CH_2)_mCH((C_1-C_{10})alkyl(C_1-C_{10})alkyl)$ ,  
 $-CO_2(C_1-C_{10})alkyl$ ,  $-(C_1-C_{10})alkyl$ ,  $-(C_2-C_{10})alkenyl$ ,  $-(C_2-C_{10})alkynyl$ ,  
 $-(C_3-C_{10})cycloalkyl$ ,  $-(C_8-C_{14})bicycloalkyl$ ,  $-(C_5-C_{10})cycloalkenyl$ ,  $-(C_5)heteroaryl$ ,  
 $-(C_6)heteroaryl$ ,  $-phenyl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})heterocycle$ ,  $-CO_2(CH_2)_m(C_1-C_{10})alkyl$ ,  
 $-CO_2(CH_2)_mH$ ,  $-NHC(O)(C_1-C_{10})alkyl$ ,  $-NHC(O)NH(C_1-C_{10})alkyl$ ,  $-NH(aryl)$ ,  
 20  $-N=C(aryl)$ ,  $-OC(O)O(C_1-C_{10})alkyl$ , or  $-SO_2NH_2$ ;

$X$  is  $O$ ,  $S$ , or  $N(R_5)$ ;

$R_1$ ,  $R_2$  or  $R_3$  taken in combination can form one or more substituted or  
 unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered aromatic  
 ring;


- 25 two  $R_6$  groups on adjacent carbon atoms can together form a 5 or 6 membered  
 cyclic or heterocyclic ring or a 6-membered aromatic ring;

each  $m$  is independently an integer ranging from 0 to 8; and

each  $p$  is independently an integer ranging from 0 to 5.

In another embodiment, the inhibitor is a compound of structural formula (II):






(II)

or a pharmaceutically available solvate or hydrate thereof, wherein;

5


each of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>7</sub> and R<sub>8</sub> is independently -H, -halo, -NO<sub>2</sub>, -CN, -C(R<sub>5</sub>)<sub>3</sub>,  
 -(CH<sub>2</sub>)<sub>m</sub>OH, -N(R<sub>5</sub>)(R<sub>5</sub>), -O(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>),  
 -OCF<sub>3</sub>, -benzyl, -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl,  
 -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl,  
 10 -(C<sub>6</sub>)heteroaryl, -(C<sub>5</sub>-C<sub>10</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>,  
 -N(OH)aryl, -NHC(O)R<sub>5</sub>, -NHC(O)OR<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -heterocylcoalkyl,  
 -C(S)N(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkylNHC(O)(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkylNR<sub>5</sub>R<sub>5</sub>,  
 -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>,  
 -S(O)<sub>2</sub>NHR<sub>5</sub>, or

15



R<sub>3</sub> is -H -C(R<sub>5</sub>)<sub>3</sub>, -(CH<sub>2</sub>)<sub>m</sub>OH, -C(O)R<sub>5</sub>, -C(O)NR<sub>5</sub>R<sub>5</sub>, -C(O)NH(CH<sub>2</sub>)<sub>m</sub>(R<sub>5</sub>), -benzyl,  
 -CO<sub>2</sub>CH(R<sub>5</sub>)(R<sub>5</sub>), -(C<sub>1</sub>-C<sub>10</sub>)alkyl, -(C<sub>2</sub>-C<sub>10</sub>)alkenyl, -(C<sub>2</sub>-C<sub>10</sub>)alkynyl,  
 -(C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -(C<sub>8</sub>-C<sub>14</sub>)bicycloalkyl, -(C<sub>5</sub>-C<sub>10</sub>)cycloalkenyl, -(C<sub>5</sub>)heteroaryl,  
 20 -(C<sub>6</sub>)heteroaryl, -(C<sub>5</sub>-C<sub>10</sub>)heteroaryl, -naphthyl, -(C<sub>3</sub>-C<sub>10</sub>)heterocycle, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>,  
 -N(OH)aryl, -NHC(O)R<sub>5</sub>, -NHC(O)OR<sub>5</sub>, -NHC(O)NHR<sub>5</sub>, -N=C(aryl),  
 -heterocylcoalkyl, -(C<sub>1</sub>-C<sub>10</sub>)alkylNHC(O)(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>, -(C<sub>1</sub>-C<sub>10</sub>)alkylNR<sub>5</sub>R<sub>5</sub>,  
 -OC(O)(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -CO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>CHR<sub>5</sub>R<sub>5</sub>, -OC(O)OR<sub>5</sub>, -SR<sub>5</sub>, -S(O)R<sub>5</sub>, -S(O)<sub>2</sub>R<sub>5</sub>,  
 -S(O)<sub>2</sub>NHR<sub>5</sub>, or

25



wherein;

each  $R_5$  and  $R_6$  is independently  $-H$ ,  $-halo$ ,  $-NO_2$ ,  $-CN$ ,  $-OH$ ,  $-CO_2H$ ,

$-N(C_1-C_{10})alkyl(C_1-C_{10})alkyl$ ,  $-O(C_1-C_{10})alkyl$ ,  $-C(O)(C_1-C_{10})alkyl$ ,

- 5  $-C(O)NH(CH_2)_m(C_1-C_{10})alkyl$ ,  $-OCF_3$ ,  $-benzyl$ ,  $-CO_2(CH_2)_mCH((C_1-C_{10})alkyl(C_1-C_{10})alkyl)$ ,  $-CO_2(C_1-C_{10})alkyl$ ,  $-(C_1-C_{10})alkyl$ ,  $-(C_2-C_{10})alkenyl$ ,  $-(C_2-C_{10})alkynyl$ ,  $-(C_3-C_{10})cycloalkyl$ ,  $-(C_8-C_{14})bicycloalkyl$ ,  $-(C_5-C_{10})cycloalkenyl$ ,  $-(C_5)heteroaryl$ ,  $-(C_6)heteroaryl$ ,  $-phenyl$ ,  $-naphthyl$ ,  $-(C_3-C_{10})heterocycle$ ,  $-CO_2(CH_2)_m(C_1-C_{10})alkyl$ ,  $-CO_2(CH_2)_mH$ ,  $-NHC(O)(C_1-C_{10})alkyl$ ,  $-NHC(O)NH(C_1-C_{10})alkyl$ ,  $-NH(aryl)$ ,  
10  $-N=C(aryl)$ ,  $-OC(O)O(C_1-C_{10})alkyl$ , or  $-SO_2NH_2$ ;





$X$  is  $O$ ,  $S$ , or  $N(R_5)$ ;

$R_1$  and  $R_2$ ,  $R_2$  and  $R_3$ ,  $R_3$  and  $R_4$ ,  $R_4$  and  $R_7$ , or  $R_7$  and  $R_8$  taken in combination can form one or more substituted or unsubstituted 5 or 6 membered cyclic or heterocyclic rings or a 6-membered aromatic ring;

- 15 two  $R_6$  groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or heterocyclic ring or a 6-membered aromatic ring;  
each  $m$  is independently an integer ranging from 0 to 8; and  
each  $p$  is independently an integer ranging from 0 to 5.

- 20 The Edg-2 modulators can also include the following compounds:

25



Those of skill in the art will appreciate that the Edg-3 receptor is a G protein  
 5 coupled receptor. The Edg-3 receptor is encoded by an endothelial differentiation  
 gene. Preferably, the Edg-3 receptor is a human receptor.

The Edg-3 receptor may be expressed by recombinant DNA methods well  
 known to those of skill in the art. Particularly useful cell types for expressing and  
 assaying Edg-3 include, but are not limited to, HTC4 (rat hepatoma cells), RH7777  
 10 (rat hepatoma cells), HepG2 (human hepatoma cells), CHO (Chinese hamster ovary  
 cells) and HEK-293 (human embryonic kidney cells). Particularly useful vectors for  
 expressing G-protein receptors include, but are not limited to, pLXSN and pCMV  
 (Clontech Labs, Palo Alto, CA; Invitrogen Corporation, Carlsbad, CA).

DNA encoding Edg-3 is well known (*e.g.*, human Edg-2, GenBank Accession  
 15 No., X83864) and can be transfected into human or mammalian cells according to  
 methods known to those of skill in the art. For example, DNA encoding human Edg-  
 2 can be co-transfected with a standard packaging vector, such as those described  
 above, which provides an ecotropic envelope for viral replication, into a packaging  
 cell line such as GP-293 (Clontech Labs, Palo Alto, CA).

20 Alternatively, DNA encoding Edg-2 can be transfected into the EcoPack-293  
 cell line which has, in addition to *gag* and *pol*, the *env* gene to produce an ecotropic

envelope. Both methods (*i.e.* co-transfection with a packaging vector or use of EcoPack-293) enable the production of an ecotropic envelope for viral packaging, and can thus advantageously be used to transfect rat and mouse cells. For use in human and other mammalian cells, AmphoPack-293 cell line can be used (Clontech Labs,  
5 Palo Alto, CA).

Those of skill in the art will appreciate that cells which express the Edg-3 receptor may grown *in vitro* or may be part of a complex organism such as, for example, a mammal. It is contemplated that the methods of the current invention will be applicable to modulation of the Edg-3 receptor activity regardless of the local  
10 environment. In one preferred embodiment, cells that express the Edg-3 receptor are grown *in vitro* (*i.e.*, are cultured). In another preferred embodiment, cells that express the Edg-3 receptor are *in vivo* (*i.e.*, are part of a complex organism).

The cells, in which the method of the invention may be practiced include, but are not limited to, hepatoma cells, ovarian cells, epithelial cells, fibroblast cells,  
15 neuronal cells, cardiac myocytes, carcinoma cells, pheochromocytoma cells, myoblast cells, endothelial cells, platelet cells and fibrosarcoma cells. More specifically, the cells in which the invention may be practiced include, but are not limited to, OV202 human ovarian cell, HTC rat hepatoma cells, CAOV-3 and SKOV-3 human ovarian cancer cells, MDA-MB-453 breast cancer cells, MDA-MB-231 breast cancer cells,  
20 A431 human epitheloid carcinoma cells and HT-1080 human fibrosarcoma cells.

In a second aspect, an Edg-3 receptor mediated biological activity is modulated in a subject or in an animal model. A therapeutically effective amount of an modulator of the Edg-3 receptor is administered to the subject or an animal. Preferably, the subject or animal is in need of such treatment.

25 The biological activity mediated by the Edg-3 receptor may include, for example, calcium mobilization, VEGF synthesis, IL-8 synthesis, platelet activation, cell migration, phosphoinositide hydrolysis, inhibition of cAMP formation or actin polymerization. Preferably, the biological activity mediated by the Edg-3 receptor includes, but is not limited to, apoptosis, angiogenesis, inhibition of wound healing,  
30 inflammation, cancer invasiveness or atherogenesis. Most preferably, the biological activity mediated by the Edg-3 receptor is cell proliferation, which may lead to ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer or prostrate cancer. In one embodiment, cell proliferation is stimulated by LPA.

In another embodiment, the biological activity mediated by the Edg-3 receptor may include increasing fatty acids levels (e.g., free fatty acids and lyso-phosphatidylcholine) which may lead to acute lung diseases, such as adult respiratory distress syndrome (“ARDS”) and acute inflammatory exacerbation of chronic lung diseases like asthma.

In yet another embodiment, compounds that block Edg-3 can be potentially effective immunosuppressive agents because activated T cells have Edg-3 receptors. Edg-3 antagonists may be useful in a variety of autoimmune and related immune disorders, including, but not limited to, systemic lupus erythematosus (SLE), rheumatoid arthritis, non-glomerular nephrosis, psoriasis, chronic active hepatitis, ulcerative colitis, Crohn’s disease, Behçet’s disease, chronic glomerulonephritis, chronic thrombocytopenic purpura, and autoimmune hemolytic anemia. Additionally, Edg-3 antagonists can be used in organ transplantation.

In one embodiment, the modulator exhibits selectivity for the Edg-3 receptor. For example, the modulator exhibits at least about 5 to about 200 fold inhibitory selectivity for Edg-3 relative to other Edg receptors. Inhibitory selectivity, can be measured by assays such as a calcium mobilization assay or a migration and/or invasion assay or a proliferation assay, for example, as described in Section 6.5 (Example 5), 6.7 (Example 7) and 6.8 (Example 8) respectively. In a preferred embodiment, inhibitory selectivity can be measured by a calcium mobilization assay. Other assays suitable for determining inhibitory selectivity would be known to one of skill in the art.

In another embodiment, the modulator exhibits at least about 200 fold inhibitory selectivity for Edg-3 relative to other non-Edg receptors, GPCRs, growth factor receptors, ion channels and the like.

In another embodiment, the modulator exhibits at least about 40 fold inhibitory selectivity for Edg-3 relative to other Edg receptors.

In another embodiment, the modulator exhibits at least about 12 fold inhibitory selectivity for Edg-3 relative to other Edg receptors.

In another embodiment, the modulator exhibits at least about 5 fold inhibitory selectivity for Edg-3 relative to other Edg receptors.

In still another embodiment, the modulator exhibits at least about 200 fold inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In still another embodiment, the modulator exhibits at least about 40 fold inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In still another embodiment, the modulator exhibits at least about 12 fold inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

5 In still another embodiment, the modulator exhibits at least about 5 inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In a preferred embodiment, an modulator of cell proliferation exhibits at least about 200 fold inhibitory selectivity for Edg-3 relative to other Edg receptors.

10 In another embodiment, the modulator of cell proliferation exhibits at least about 5 fold inhibitory selectivity for Edg-3 relative to other Edg receptors.

In still another embodiment, the modulator of cell proliferation exhibits at least about 200 fold inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

15 In still another embodiment, the modulator of cell proliferation exhibits at least about 5 fold inhibitory selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In another embodiment, the modulator exhibits activating selectivity for the Edg-3 receptor. For example, the modulator exhibits at least about 5 to about 200 fold activating selectivity for Edg-3 relative to other Edg receptors. Activating selectivity, can be measured by assays such as a calcium mobilization assay or a migration and/or invasion assay or a proliferation assay, for example, as described in Section 6.5 (Example 5), 6.7 (Example 7) and 6.8 (Example 8) respectively. In a preferred embodiment, activating selectivity can be measured by a calcium mobilization assay. Other assays suitable for determining activating selectivity would  
20 be known to one of skill in the art.

In another embodiment, the modulator exhibits at least about 200 fold activating selectivity for Edg-3 relative to other non-Edg receptors, GPCRs, growth factor receptors, ion channels and the like.

30 In another embodiment, the modulator exhibits at least about 40 fold activating selectivity for Edg-3 relative to other Edg receptors.

In another embodiment, the modulator exhibits at least about 12 fold activating selectivity for Edg-3 relative to other Edg receptors.

In another embodiment, the modulator exhibits at least about 5 fold activating selectivity for Edg-3 relative to other Edg receptors.

In still another embodiment, the modulator exhibits at least about 200 fold activating selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In still another embodiment, the modulator exhibits at least about 40 fold activating selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

5 In still another embodiment, the modulator exhibits at least about 12 fold activating selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In still another embodiment, the modulator exhibits at least about 5 activating selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

10 In a preferred embodiment, an modulator of cell proliferation exhibits at least about 200 fold activating selectivity for Edg-3 relative to other Edg receptors.

In another embodiment, the modulator of cell proliferation exhibits at least about 5 fold activating selectivity for Edg-3 relative to other Edg receptors.

In still another embodiment, the modulator of cell proliferation exhibits at least about 200 fold activating selectivity for Edg-3 relative to Edg-4 and Edg-7  
15 receptors.

In still another embodiment, the modulator of cell proliferation exhibits at least about 5 fold activating selectivity for Edg-3 relative to Edg-4 and Edg-7 receptors.

In one embodiment, the Edg-3 modulator is not a lipid. In another  
20 embodiment, the modulator of Edg-3 modulator does not contain a phosphate group such as a phosphoric acid, a cyclic phosphate ester or a linear phosphate ester. In another embodiment, the Edg-3 modulator is not a phospholipid. The term “phospholipid” includes all phosphate (both phosphate esters and phosphoric acids) containing glycerol derivatives with an alkyl chain of 10 carbon atoms or greater,  
25 dioctyl glycerol, any N-acyl ethanolamide phosphate derivative (both phosphate esters and phosphoric acids), LPA, S1P or any of their analogues (both phosphate esters and phosphoric acids) (see, e.g., Bando et al., 2000, *FEBS Lett.* 428, 759; Bittman et al., 1996, *J. Lipid Research* 391; Lilliom et al., 1996, *Molecular Pharmacology* 616, Hooks et al., 1998, *Molecular Pharmacology* 188; Fischer et al., 1998, *Molecular  
30 Pharmacology* 979; Heise et al., 2001, *Molecular Pharmacology* 1173; Hopper et al., 1999, *J. Med. Chem.* 42 (6):963-970; Tigyi et al., 2001, *Molecular Pharmacology* 1161).

In one embodiment, the Edg-3 modulator is an agonist of the Edg-3 receptor. In one aspect, such an embodiment provides an Edg-3 modulator that is an agonist,

but is a weaker agonist than a natural Edg-3 agonist (*e.g.*, LPA) and as such, may compete with the natural agonist for Edg-3 binding site, resulting in a net inhibition of Edg-3 receptor activity.

5 In another preferred embodiment, the modulator is antagonist of the Edg-3 receptor. The Edg-3 modulator may be a biomolecule such as a nucleic acid, protein (*e.g.*, an enzyme, an antibody or a soluble Edg-3 receptor polypeptide) or oligosaccharide or any combination thereof. Alternatively, the Edg-3 modulator may be oligomers or monomers of the above biomolecules such as amino acids, peptides, monosaccharides, disaccharides, nucleic acid monomers, dimers, *etc.*, or any  
10 combination thereof. The Edg-3 modulator may also be a synthetic polymer or any combination of synthetic polymer with biomolecules including monomers or oligomers of biomolecules.

The Edg-3 modulator may also be a small organic molecule. In particular embodiments, such a small organic molecule exhibits a molecular weight about 200 to  
15 about 1000 daltons, about about 200 to about 750 daltons, 200 to about 500 daltons, or about 300 to about 500 daltons. In a particularly preferred embodiment, the small organic molecule can be orally administered to a subject. In another preferred embodiment, the small organic molecule is capable of crossing the blood-brain barrier.

20 Without wishing to be bound by any particular theory or understanding, the modulator may, for example, facilitate inhibition of the Edg-3 receptor through direct binding to the LPA binding site of the receptor, binding at some other site of the Edg-3 receptor, interference with Edg-3 biosynthesis, covalent modification of the Edg-3 receptor, or may otherwise interfere with Edg-2 mediated signal transduction.

25 In one embodiment, the agonist or antagonist binds to the Edg-3 receptor with a binding constant between about 10  $\mu$ M and 1 fM. In another embodiment, the agonist or antagonist binds to the Edg-3 receptor with a binding constant between about 10  $\mu$ M and about 1 nM. In another embodiment, the agonist or antagonist binds to the Edg-3 receptor with a binding constant between about 1  $\mu$ M and about 1 nM.  
30 In another embodiment, the agonist or antagonist binds to the Edg-3 receptor with a binding constant between about 100 nM and about 1 nM. In another embodiment, the agonist or antagonist binds to the Edg-3 receptor with a binding constant between



about 10 nM and about 1 nM. Preferably, the agonist or antagonist binds to the Edg-3 receptor with a binding constant better (*i.e.*, less) than about 10 nM.

The compounds of the invention may be more suitable for pharmaceutical development and may have more specific pharmacological modes of action than currently known Edg receptor ligands. The present invention provides methods for inhibiting Edg-3 receptor mediated biological activity. The present invention also provides methods for using Edg-3 modulators (agonists and antagonists) in treating or preventing diseases such as ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer; acute lung diseases, adult respiratory distress syndrome ("ARDS"), acute inflammatory exacerbation of chronic lung diseases such as asthma, surface epithelial cell injury, (*e.g.*, transcorneal freezing or cutaneous burns) and cardiovascular diseases (*e.g.*, ischemia) in a subject in need of such treatment or prevention. Further, the present invention provides compounds and compositions that can, for example, be used in modulating Edg-3 receptor mediated biological activity or treating or preventing diseases such as those mentioned above.

In one aspect, the present invention provides a method of inhibiting an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with an amount of an Edg-3 receptor inhibitor sufficient to inhibit the Edg-3 receptor mediated biological activity. Preferably, the inhibitor is not a phospholipid.

In a second aspect, the present invention provides a method where an Edg-3 receptor mediated biological activity is inhibited in a subject. A therapeutically effective amount of an inhibitor of the Edg-3 receptor is administered to the subject. Preferably, the inhibitor is not a phospholipid.

## **5.2. Synthesis of the Compounds of the Invention**

The compounds of the invention may be obtained *via* the synthetic methods illustrated in Schemes 1 and 2. Starting materials useful for preparing compounds of the invention and intermediates thereof are commercially available or can be prepared by well-known synthetic methods. Other methods for synthesis of the compounds described herein are either described in the art or will be readily apparent to the skilled artisan in view of general references well-known in the art (See *e.g.*, Green *et al.*, "Protective Groups in Organic Chemistry", (Wiley, 2<sup>nd</sup> ed. 1991); Harrison *et al.*,

“Compendium of Synthetic Organic Methods”, Vols. 1-8 (John Wiley and Sons, 1971-1996); “Beilstein Handbook of Organic Chemistry,” Beilstein Institute of Organic Chemistry, Frankfurt, Germany; Feiser *et al.*, “Reagents for Organic Synthesis,” Volumes 1-17, Wiley Interscience; Trost *et al.*, “Comprehensive Organic Synthesis,” Pergamon Press, 1991; “Theilheimer’s Synthetic Methods of Organic Chemistry,” Volumes 1-45, Karger, 1991; March, “Advanced Organic Chemistry,” Wiley Interscience, 1991; Larock “Comprehensive Organic Transformations,” VCH Publishers, 1989; Paquette, “Encyclopedia of Reagents for Organic Synthesis,” John Wiley & Sons, 1995) and may be used to synthesize the compounds of the invention. Compounds of formula 113, 115, and 119 are commercially available from Asinex. Compound 117 is commercially available from Chemdiv.

### 5.3. Therapeutic Uses of the Compounds of the Invention

The compounds and/or compositions of the present invention may be used to prevent and/or treat diseases, including but not limited to, ovarian cancer (Xu *et al.*, 1995, *Biochem. J.* 309 (Pt 3):933-940; Xu *et al.*, 1998, *JAMA* 280 (8):719-723; Goetzl *et al.*, 1999, *Cancer Res.* 59 (20):5370-5375), peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer; acute lung diseases, adult respiratory distress syndrome (“ARDS”), acute inflammatory exacerbation of chronic lung diseases such as asthma (Chilton *et al.*, 1996, *J Exp Med* 183:2235-45; Arbibe *et al.*, 1998, *J Clin Invest* 102:1152-60) surface epithelial cell injury, (e.g., transcorneal freezing or cutaneous burns (Liliom *et al.*, 1998, *Am. J. Physiol* 274 (4 Pt 1):C1065-C1074)), cardiovascular diseases, (e.g., ischemia (Karlner *et al.*, 2001, *J. Mol. Cell Cardiol.* 33 (9):1713-1717) and atherosclerosis (Siess *et al.*, 1999, *Proc. Natl. Acad. Sci. U.S.A* 96 (12):6931-6936; Siess *et al.*, 2000, *IUBMB.B Life* 49 (3):167-171)). In accordance with the invention, a compound and/or composition of the invention is administered to a patient, preferably a human, in need of treatment for a disease which includes but is not limited to, the diseases listed above. Further, in certain embodiments, the compounds and/or compositions of the invention can be administered to a patient, preferably a human, as a preventative measure against diseases or disorders such as those depicted above. Thus, the compounds and/or compositions of the invention can be administered as a preventative measure to a patient having a predisposition, which

includes but is not limited to, the diseases listed above. Accordingly, the compounds and/or compositions of the invention may be used for the prevention of one disease or disorder and concurrently treating another disease (*e.g.*, preventing cancer and treating cardiovascular diseases). It is well within the capability of those of skill in the art to assay and use the compounds and/or compositions of the invention to treat diseases, such as the diseases listed above.

#### **5.4. Therapeutic/Prophylactic Administration**

The compounds and/or compositions of the invention may be advantageously used in medicine, including human medicine. As previously described in Section 5.4 above, compounds and compositions of the invention are useful for the treatment or prevention of diseases, which include but are not limited to, cancers, including, but not limited to, ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, prostate cancer, acute lung diseases, including, but not limited to, adult respiratory distress syndrome (ARDS) and acute inflammatory exacerbation of chronic lung diseases such as asthma; surface epithelial cell injury, including, but not limited to, transcorneal freezing or cutaneous burns; cardiovascular diseases, including, but not limited to, ischemia and atherosclerosis.

When used to treat or prevent disease or disorders, compounds and/or compositions of the invention may be administered or applied singly, in combination with other agents. The compounds and/or compositions of the invention may also be administered or applied singly, in combination with other pharmaceutically active agents, including other compounds and/or compositions of the invention.

The current invention provides methods of treatment and prophylaxis by administration to a patient of a therapeutically effective amount of a composition or compound of the invention. The patient may be an animal, is more preferably a mammal, and most preferably a human.

The present compounds and/or compositions of the invention, which comprise one or more compounds of the invention, are preferably administered orally. The compounds and/or compositions of the invention may also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal

mucosa, *etc.*). Administration can be systemic or local. Various delivery systems are known, (*e.g.*, encapsulation in liposomes, microparticles, microcapsules, capsules, *etc.*) that can be used to administer a compound and/or composition of the invention. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The preferred mode of administration is left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition. In most instances, administration will result in the release of the compounds and/or compositions of the invention into the bloodstream.

In specific embodiments, it may be desirable to administer one or more compounds and/or composition of the invention locally to the area in need of treatment. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of the disease.

In certain embodiments, it may be desirable to introduce one or more compounds and/or compositions of the invention into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

A compound and/or composition of the invention may also be administered directly to the lung by inhalation. For administration by inhalation, a compound and/or composition of the invention may be conveniently delivered to the lung by a number of different devices. For example, a Metered Dose Inhaler ("MDI"), which utilizes canisters that contain a suitable low boiling propellant, (*e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or any other suitable gas) may be used to deliver compounds of the invention directly to the lung.

Alternatively, a Dry Powder Inhaler ("DPI") device may be used to administer a compound and/or composition of the invention to the lung. DPI devices typically

use a mechanism such as a burst of gas to create a cloud of dry powder inside a container, which may then be inhaled by the patient. DPI devices are also well known in the art. A popular variation is the multiple dose DPI ("MDDPI") system, which allows for the delivery of more than one therapeutic dose. For example, capsules and  
5 cartridges of gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch for these systems.

Another type of device that may be used to deliver a compound and/or a composition of the invention to the lung is a liquid spray device. Liquid spray  
10 systems use extremely small nozzle holes to aerosolize liquid drug formulations that may then be directly inhaled into the lung.

In one embodiment, a nebulizer is used to deliver a compound and/or composition of the invention to the lung. Nebulizers create aerosols from liquid drug formulations by using, for example, ultrasonic energy to form fine particles that may  
15 be readily inhaled (see *e.g.*, Verschoye *et al.*, *British J. Cancer* **1999**, 80, Suppl. 2, 96, which is herein incorporated by reference). Examples of nebulizers include devices supplied by Sheffield/Systemic Pulmonary Delivery Ltd. (See, Armer *et al.*, United States Patent No. 5,954,047; van der Linden *et al.*, United States Patent No. 5,950,619; van der Linden *et al.*, United States Patent No. 5,970,974), Aventis and  
20 Batelle Pulmonary Therapeutics.

In another embodiment, an electrohydrodynamic ("EHD") aerosol device is used to deliver a compound and/or composition of the invention to the lung. EHD aerosol devices use electrical energy to aerosolize liquid drug solutions or suspensions (see *e.g.*, Noakes *et al.*, United States Patent No. 4,765,539). EHD aerosol devices  
25 may more efficiently deliver drugs to the lung than other pulmonary delivery technologies.

In another embodiment, the compounds of the invention can be delivered in a vesicle, in particular a liposome (see Langer, *Science* **1990**, 249:1527-1533; Treat *et al.*, in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); see generally "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989)).  
30

In yet another embodiment, the compounds of the invention can be delivered *via* sustained release systems, preferably oral sustained release systems. In one

embodiment, a pump may be used (*see* Langer, *supra*; Sefton, 1987, *CRC Crit Ref Biomed. Eng.* 14:201; Saudek *et al.*, *N. Engl. J Med.* 1989, 321:574).

In another embodiment, polymeric materials can be used (*see* "Medical Applications of Controlled Release," Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); "Controlled Drug Bioavailability," Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol Chem.* 1983, 23:61; *see also* Levy *et al.*, *Science* 1985, 228: 190; During *et al.*, *Ann. Neurol.* 1989, 25:351; Howard *et al.*, *J. Neurosurg.* 1989, 71:105). In a preferred embodiment, polymeric materials are used for oral sustained release delivery. In another embodiment, enteric-coated preparations can be used for oral sustained release administration. In still another embodiment, osmotic delivery systems are used for oral sustained release administration (Verma *et al.*, *Drug Dev. Ind. Pharm.* 2000, 26:695-708).

In yet another embodiment, a controlled-release system can be placed in proximity of the target of the compounds and/or composition of the invention, thus requiring only a fraction of the systemic dose (*see, e.g.* Goodson, in "Medical Applications of Controlled Release," *supra*, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in Langer, 1990, *Science* 249:1527-1533 may also be used.

### 5.5. Compositions of the Invention

The present compositions contain a therapeutically effective amount of one or more compounds of the invention, preferably in purified form, together with a suitable amount of a pharmaceutically acceptable vehicle, so as to provide the form for proper administration to a patient. When administered to a patient, the compounds of the invention and pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying

agents or pH buffering agents. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used.

Pharmaceutical compositions comprising a compound of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-  
5 making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries, which facilitate processing of compounds of the invention into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of  
10 administration chosen.

The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the  
15 pharmaceutically acceptable vehicle is a capsule (see *e.g.*, Grosswald *et al.*, United States Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles have been described in the art (see Remington's Pharmaceutical Sciences, Philadelphia College of Pharmacy and Science, 17th Edition, 1985).

For topical administration compounds of the invention may be formulated as  
20 solutions, gels, ointments, creams, suspensions, *etc.* as are well-known in the art.

Systemic formulations include those designed for administration by injection, *e.g.*, subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration. Systemic formulations may be made in combination with a further  
25 active agent that improves mucociliary clearance of airway mucus or reduces mucous viscosity. These active agents include, but are not limited to, sodium channel blockers, antibiotics, N-acetyl cysteine, homocysteine and phospholipids.

In a preferred embodiment, the compounds of the invention are formulated in accordance with routine procedures as a composition adapted for intravenous  
30 administration to human beings. Typically, compounds of the invention for intravenous administration are solutions in sterile isotonic aqueous buffer. For injection, a compound of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents

such as suspending, stabilizing and/or dispersing agents. When necessary, the compositions may also include a solubilizing agent. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either  
5 separately or mixed together in unit dosage form, for example, as a lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. When the compound of the invention is administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. When the  
10 compound of the invention is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the  
15 art.

Compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions may contain one or more optionally agents, for example, sweetening agents such as fructose, aspartame or  
20 saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry coloring agents and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Selectively permeable membranes  
25 surrounding an osmotically active driving compound are also suitable for orally administered compounds of the invention. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the  
30 spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Such vehicles are preferably of pharmaceutical grade.



For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, saline, alkylene glycols (*e.g.*, propylene glycol), polyalkylene glycols (*e.g.*, polyethylene glycol) oils, alcohols, slightly acidic buffers between pH 4 and pH 6 (*e.g.*, acetate, citrate, ascorbate at between about 5.0 mM to about 50.0 mM, *etc.*). Additionally, 5 flavoring agents, preservatives, coloring agents, bile salts, acylcarnitines and the like may be added.

For buccal administration, the compositions may take the form of tablets, lozenges, *etc.* formulated in conventional manner.

10 Liquid drug formulations suitable for use with nebulizers and liquid spray devices and EHD aerosol devices will typically include a compound of the invention with a pharmaceutically acceptable vehicle. Preferably, the pharmaceutically acceptable vehicle is a liquid such as alcohol, water, polyethylene glycol or a perfluorocarbon. Optionally, another material may be added to alter the aerosol 15 properties of the solution or suspension of compounds of the invention. Preferably, this material is liquid such as an alcohol, glycol, polyglycol or a fatty acid. Other methods of formulating liquid drug solutions or suspension suitable for use in aerosol devices are known to those of skill in the art (see, *e.g.*, Biesalski, United States Patent No. 5,112,598; Biesalski, United States Patent No. 5,556,611).

20 A compound of the invention may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, a compound of the invention may also be formulated as a depot preparation. Such long acting 25 formulations may be administered by implantation (*e.g.*, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, a compound of the invention may be formulated with suitable polymeric or hydrophobic materials (*e.g.*, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

30 When a compound of the invention is acidic, it may be included in any of the above-described formulations as the free acid, a pharmaceutically acceptable salt, a solvate or hydrate. Pharmaceutically acceptable salts substantially retain the activity of the free acid, may be prepared by reaction with bases and tend to be more soluble in aqueous and other protic solvents than the corresponding free acid form.

## 5.6. Methods of Use And Doses

A compound of the invention, or compositions thereof, will generally be used in an amount effective to achieve the intended purpose. The compounds of the invention or compositions thereof, are administered or applied in a therapeutically effective amount for use to treat or prevent diseases or disorders including, but not limited to, ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, prostate cancer, acute lung diseases, (*e.g.*, adult respiratory distress syndrome (ARDS) and asthma) surface epithelial cell injury (*e.g.*, transcorneal freezing and cutaneous burns) and cardiovascular diseases such as ischemia and atherosclerosis. Compounds of the invention or compositions thereof, are administered or applied in a therapeutically effective amount.

The amount of a compound of the invention that will be effective in the treatment of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques known in the art as previously described. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The amount of a compound of the invention administered will, of course, be dependent on, among other factors, the subject being treated, the weight of the subject, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

For example, the dosage may be delivered in a pharmaceutical composition by a single administration, by multiple applications or controlled release. In a preferred embodiment, the compounds of the invention are delivered by oral sustained release administration. Preferably, in this embodiment, the compounds of the invention are administered twice per day (more preferably, once per day). Dosing may be repeated intermittently, may be provided alone or in combination with other drugs and may continue as long as required for effective treatment of the disease state or disorder.

Suitable dosage ranges for oral administration are dependent on the potency of the, but are generally about 0.001 mg to about 200 mg of a compound of the invention per kilogram body weight. Dosage ranges may be readily determined by methods known to the skilled artisan.

Suitable dosage ranges for intravenous (i.v.) administration are about 0.01 mg to about 100 mg per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 mg/kg body weight to about 1 mg/kg body weight. Suppositories generally contain about 0.01 milligram to about 50 milligrams of a compound of the invention per kilogram body weight and comprise active ingredient in the range of about 0.5% to about 10% by weight. Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual or intracerebral administration are in the range of about 0.001 mg to about 200 mg per kilogram of body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Such animal models and systems are well known in the art.

The compounds of the invention are preferably assayed *in vitro* and *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays can be used to determine whether administration of a specific compound of the invention or a combination of compounds of the invention is preferred for reducing convulsion. The compounds of the invention may also be demonstrated to be effective and safe using animal model systems.

Preferably, a therapeutically effective dose of a compound of the invention described herein will provide therapeutic benefit without causing substantial toxicity. Toxicity of compounds of the invention may be determined using standard pharmaceutical procedures and may be readily ascertained by the skilled artisan. The dose ratio between toxic and therapeutic effect is the therapeutic index. A compound of the invention will preferably exhibit particularly high therapeutic indices in treating disease and disorders. The dosage of a compound of the inventions described herein will preferably be within a range of circulating concentrations that include an effective dose with little or no toxicity.

#### **5.7. Combination Therapy**

In certain embodiments, the compounds of the invention can be used in combination therapy with at least one other therapeutic agent. The compound of the invention and the other therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, a compound of the invention is administered concurrently with the administration of another therapeutic agent. In another preferred embodiment, a composition comprising a compound of the

invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as the compound of the invention or a different composition. In another embodiment, a composition comprising a compound of the invention is administered prior or subsequent to administration of another therapeutic agent. Other therapeutic agents, which may be used with the compounds and/or compositions of the invention, include but are not limited to, agonists and antagonists of Edg-3, other Edg-receptors, drugs used to treat cardiovascular diseases and/or cancer such as, alkylating agents (*e.g.*, cyclophosphamide, melphalan, chlorambucil), platinum compounds (*e.g.*, cisplatin, carboplatin), anthracyclines (*e.g.*, doxorubicin, epirubicin), taxanes (*e.g.*, paclitaxel, docetaxel), chronic oral etoposide, topotecan, gemcitabine, hexamethylamine, methotrexate, and 5-fluorouracil.

## 5.8. Assays

One of skill in the art can use the following assays, for example, to routinely identify and test Edg-3 agonists or antagonists, including Edg-3 selective agonists and antagonists.

### 5.8.1 Intracellular Calcium Measurement Assays

Specific assays for Edg-3 receptor activity are known to those of skill in the art. For example, cells expressing Edg-3 receptors can be contacted with a membrane-permeant calcium sensitive dye such as Fluo-4 AM or a proprietary calcium dye loading kit (*e.g.*, FLIPR Calcium Assay kit, Molecular Devices, Sunnyvale, CA). Intracellular calcium is capable of binding to the dye and emitting fluorescent radiation when illuminated at the appropriate wavelength. The cells can thus be illuminated an appropriate wavelength for the dye and any emitting light can be captured by a cooled CCD camera. Changes in fluorescence indicate changes in intracellular calcium resulting from the activation of an Edg-2 receptor. Such changes can be measured advantageously in whole cells in "real-time" (Berridge *et al.*, Nature Reviews 2000, 1:11-21).

Other methods of measuring intracellular calcium are known to those of skill in the art. For instance, a commonly used technique is the expression of receptors of interest in *Xenopus laevis* oocytes followed by measurement of calcium activated chloride currents (see Weber, 1999, *Biochim Biophys Acta* 1421:213-233). In

addition, several calcium sensitive dyes are available for the measurement of intracellular calcium. Such dyes can be membrane permeant or not membrane permeant. Examples of useful membrane permeant dyes include acetoxymethyl ester forms of dyes that can be cleaved by intracellular esterases to form a free acid, which is no longer membrane permeant and remains trapped inside a cell. Dyes that are not membrane permeant can be introduced into the cell by microinjection, chemical permeabilization, scrape loading and similar techniques (Haughland, 1993, in "Fluorescent and Luminescent Probes for Biological Activity" ed. Mason, W.T. pp 34-43; Academic Press, London; Haughland, 1996, in "Handbook of Fluorescent Probes and Research Chemicals", sixth edition, Molecular Probes, Eugene, OR).

### 5.8.2 IL-8 and VEGF Assays

The levels of interleukin-8 ("IL-8") and vascular endothelial growth factor ("VEGF") are important markers for the proliferative potential, angiogenic capacity and metastatic potential of a tumor cell line. Specific assays for IL-8 and VEGF are known to those of skill in the art. For example, IL-8 and VEGF assays can be performed by techniques that include, but are not limited to, a standard enzyme-linked immunosorbent assay ("ELISA"). In a standard ELISA, the cells can be cultured, for example, in a 96 well format, serum starved overnight, and treated with LPA or S1P. Dose ranges would be known to one of skill in the art. For example, the doses can range from 0.1-10  $\mu$ M in serum free medium. Cell supernatants can then be collected to measure the amount of IL-8 or VEGF secreted.

Methods to measure the amount of IL-8 or VEGF secreted are known to one of skill in the art. In one method, an anti-IL-8 or anti-VEGF capture antibody can be adsorbed on to any surface, for example, a plastic dish. Cell supernatants containing IL-8 or VEGF can then be added to the dish and any method known in the art for detecting antibodies can be used to detect the anti-IL-8 or anti-VEGF antibody. In one embodiment, an anti-IL-8 or anti-VEGF biotinylated detection antibody and streptavidin-HRP can be used for detection via the addition of a substrate solution and colorimetric reading using a microtiter plate reader. The level of IL-8 or VEGF can be interpolated by non-linear regression analysis from a standard curve.

### 5.8.3. Migration and Invasion Assays

Migration and invasion assays are known to one of skill in the art. For example, migration assays can be designed to measure the chemotactic potential of the cell line, or its movement toward a concentration gradient of chemoattractants, such as, but not limited to, LPA or S1P. Invasion assays can be designed, for example, to evaluate the ability of the cell line to pass through a basement membrane, a key feature of metastasis formation.

Specific assays, known to one of skill in the art include a modified Boyden Chamber assay in which a cell suspension can be prepared in serum free medium and added to the top chamber. The concentration of cells to be added, for example, about  $10^5$  cells/ml is known to one of skill in the art. An appropriate dose of a chemoattractant can then be added to the bottom chamber. Following an incubation period, the number of cells invading the lower chamber can be quantified by methods known in the art. In one embodiment, Fluoroblok filter inserts can be used and the number of cells migrating to the lower chamber can be quantified by staining the filter inserts and detecting the fluorescence by any means known in the art. The level of fluorescence may be correlated with the number of migrating cells.

### 5.8.4 Proliferation Assay

Proliferation assays quantitate the extent of cellular proliferation in response to a stimulant, which, in the case of Edg-3 receptor, may be LPA. Cells can be plated and treated with the stimulant (*e.g.*, LPA) with or without any serum starvation. Stimulant doses may range from 0.1 to 10  $\mu$ M and in any event may be readily determined by those of skill in the art. Typically, the cells can be treated for a period of a few hours to a few days before cellular proliferation is measured.

Specific methods to determine the extent of cell proliferation are known to one of skill in the art. For example, one method is bioluminescent measurement of ATP, which is present in all metabolically active cells. ATP can be extracted by addition of Nucleotide Releasing Reagent and its release can be monitored by the addition of the ATP Monitoring Reagent. An enzyme, such as luciferase, which catalyzes the formation of light from ATP and luciferin, can be used to quantitate the amount of ATP present.

### 5.8.5 Cyclic AMP Assay

Because cAMP acts a second messenger in cell signaling, activating protein kinases that in turn phosphorylate enzymes and transcription factors, cAMP concentration is frequently indicative of the activation state of downstream signaling pathways. For GPCRs like the Edg receptors, coupling via a G $\alpha$ i pathway results in inhibition of adenylyl cyclase activity, the key enzyme involved in breakdown of ATP and formation of cAMP. Thus, assays can be designed to measure inhibition of adenylyl cyclase activity, by first stimulating cAMP formation. One example of a compound, which stimulates cAMP formation is forskolin. Forskolin bypasses the receptor and directly activates adenylyl cyclase. Under these conditions, activation of a G $\alpha$ i coupled receptor will inhibit forskolin-stimulated cAMP, and an antagonist at such a receptor will reverse the inhibition.

This assay can be performed by any means known to one of skill in the art. For example, cells can be plated and treated with or without any serum starvation. The cells may be initially treated with a compound, such as forskolin, to induce cAMP production. This is followed by the addition of an Edg-2 stimulator, for example, LPA. The dose of stimulator required is well known in the art, and could be in the range from 0.1-10  $\mu$ M in serum free medium. Following an incubation period, the cells are lysed and the level of cAMP is determined.

The cAMP assay can be performed by any means known to one of skill in the art, for example, by performing a competitive immunoassay. Cell lysates can be added to a plate precoated with anti-cAMP antibody, along with a cAMP-AP conjugate and a secondary anti-cAMP antibody. Detection can be performed by any appropriate means, including, but not limited to, using a substrate solution and chemiluminescent readout.

## 6. EXAMPLES

The invention is further defined by reference to the following examples, which describe in detail preparation of compounds and compositions of the invention and assays for using compounds and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.

### 6.1. Example 1: IL-8 and VEGF Assays

IL-8 and VEGF assays were performed by standard enzyme-linked immunosorbent assay ("ELISA") techniques. Cells were cultured in a 96 well format, serum starved overnight, and treated with LPA or S1P (doses range from 0.1-10  $\mu$ M in serum free medium) for 24 hours. Cell supernatants were then collected to measure the amount of IL-8 secreted.

The assay was a standard sandwich ELISA in which an anti-IL-8 or VEGF capture antibody was adsorbed to a plastic dish. Cell supernatants containing IL-8 or VEGF were added to the dish, and then an anti-IL-8/VEGF biotinylated detection antibody and streptavidin-HRP were added.

Detection was via the addition of a substrate solution and colorimetric reading using the BioTek EL800 microtiter plate reader. The level of IL-8 or VEGF was interpolated by non-linear regression analysis from a standard curve.

All reagents were from R&D Systems: MAB208 and AF-293-NA (capture antibody for IL-8 and VEGF respectively), BAF208 and BAF-293 (detection Ab for IL-8 and VEGF respectively), 208-IL-010 and 293-VE-010 (recombinant human IL-8 protein standard and recombinant human VEGF protein standard respectively), DY998 (streptavidin-HRP), DY999 (substrate solution). (detection antibody).

### 6.2. Example 2: Migration and Invasion Assays

Cells were plated in a 24 well format using Fluoroblok filter insert plates (8  $\mu$ M pore size) or Fluoroblok matrigel coated filter insert plates (Becton Dickinson, Catalog # 351158, 354166, respectively.) The assay was a modified Boyden Chamber assay in which a cell suspension ( $1 \times 10^5$  cells/ml) was prepared in serum free medium and added to the top chamber. LPA or S1P (doses ranged from 0.1-10  $\mu$ M in serum free medium) was added to the bottom chamber. Following a 20-24 hour incubation period, the number of cells migrating or invading into the lower chamber was quantitated by transferring the filter insert into a fresh 24-well plate containing 4  $\mu$ g/ml calcein AM (Molecular Probes, Catalog #C-1430) in Hank's Balanced Salt Solution and staining for one hour.

Detection was via fluorescent readout at 450 nm excitation/530 nm emission using the BioTek FLx800 Fluorimeter. The level of fluorescence correlated with cell number.



For most cells types, no further manipulation was required. For CaOV3 human ovarian cancer cells, however, it was necessary that the cells be serum starved overnight prior to preparing the cell suspension. In addition, the filter inserts were coated with a solution of 1 mg/ml rat-tail Collagen I (BD catalog # 354236).

5

### **6.3. Example 3: Proliferation Assay**

Cells were plated in a 96 well format. Treatments were performed directly without any serum starvation, and typically included LPA or S1P doses in a range from 0.1-10  $\mu$ M in serum free medium. Cells were treated for 24-48 before the extent of cellular proliferation was measured.

The assay was performed using the ViaLight HS kit from BioWhittaker (Catalog # LT07-211), which is based upon the bioluminescent measurement of ATP that is present in all metabolically active cells. The reaction utilized an enzyme, luciferase, which catalyzes the formation of light from ATP and luciferin. The emitted light intensity was linearly related to the ATP concentration, which correlated with cell number.

Measurement of cell proliferation required the extraction of ATP by the addition of Nucleotide Releasing Reagent, followed by the addition of the ATP Monitoring Reagent (both provided in kit). Detection was via chemiluminescence using the EG&G Berthold Luminometer.

### **6.4. Example 4: cAMP Assay**

Cells were plated in a 96 well format. Treatments were performed directly without any serum starvation. The cells were treated with forskolin to induce cAMP production, followed by LPA or S1P doses in the range from 0.1-10  $\mu$ M in serum free medium. Following a 30-minute incubation period, the cells were lysed and the level of cAMP was determined.

The cAMP assay was performed using the Tropix cAMP-Screen (Applied BioSystems Catalog # CS1000). The screen is a competitive immunoassay that utilizes a 96 well assay plate precoated with an anti-cAMP antibody. Cell lysates were added to the precoated plate, along with a cAMP-AP conjugate and a secondary anti-cAMP antibody.

Detection was performed using a substrate solution and chemiluminescent readout. The level of chemiluminescence was inversely proportional to the level of cAMP and was calculated from a standard curve.

## 5    6.6. Example 6: Pharmacology Profiling (Selectivity Assays)

In order to test the selectivity of compounds, various radioligand binding assays were performed using numerous non-Edg receptor targets as listed below.

A radioligand binding assay was performed using adrenergic  $\alpha_1$  according to the method of Greengrass and Bremner 1979, *Eur. J. Pharmacol.* 55:323-326. A  
10 radioligand binding assay was performed using adrenergic  $\alpha_2$  according to the method of Boyajian and Leslie, 1987, *J. Pharmacol. Exp. Ther.* 241:1092-1098. A radioligand binding assay was performed using adrenergic  $\beta$  according to the method of Feve *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:5677-5681. A radioligand binding assay was performed using angiotensin AT2 according to the method of Whitebread  
15 *et al.*, 1991, *Biochem. Biophys. Res. Comm.* 181:1365-1371. A radioligand binding assay was performed using calcium channel Type L, dihydropyridine according to the method of Ehlert *et al.*, 1982, *Life Sci.* 30:2191-2202. A radioligand binding assay was performed using dopamine D<sub>2L</sub> according to the method of Bunzo *et al.*, 1988, *Nature* 336:783-787. A radioligand binding assay was performed using endothelin  
20 ET<sub>A</sub> according to the method of Mihara *et al.*, 1994, *J. Pharmacol. Exp Ther.* 268:1122-1127. A radioligand binding assay was performed using histamine H<sub>1</sub> Central according to the method of Hill *et al.*, 1978, *J. Neurochem.* 31:997-1004. A radioligand binding assay was performed using Muscarinic non-selective, Central according to the method of Luthin and Wolfe, 1984, *J. Pharmacol. Exp. Ther.* 228:648-  
25 655. A radioligand binding assay was performed using serotonin 5-HT<sub>1</sub>, non-selective according to the method of Middlemiss, 1984, *Eur. J. Pharmacol.* 101:289-293).

### Radioligand Binding assays

30    1. Adrenergic  $\alpha_1$ , non-selective (Greengrass and Bremner, 1979, *Eur. J. Pharmacol.* 55:323-326).

Source: Wistar Rat brain

Ligand: 0.25 nM <sup>3</sup>H Prazosin

Vehicle: 0.4 % DMSO

- Incubation Time/Temp: 30 minutes at 25 °C  
 Incubation Buffer: 50 mM Tris-HCl, 0.1% ascorbic acid, 10 uM  
 NonSpecific Ligand: 0.1 µM Phentolamine  
 K<sub>d</sub>: 0.29 nM \*
- 5      B<sub>max</sub>: 0.095 pmol/mg Protein\*  
 Specific Binding: 90% \*  
 Quantitation Method: Radioligand Binding  
 Significance Criteria: ≥ 50% of max stimulation or inhibition
- 10      **2. Adrenergic α<sub>2</sub>** (Boyajian and Leslie, 1987, *J. Pharmacol. Exp. Ther.*  
 241:1092-1098).  
 Source: Wistar rat cerebral cortex  
 Ligand: 0.7 nM <sup>3</sup>H Rauwolscine  
 Vehicle: 0.4 % DMSO
- 15      Incubation Time/Temp: 30 minutes at 25 °C  
 Incubation Buffer: 20 mM HEPES, 2.5 mM Tris-HCl, pH 7.4 at 25 °C  
 NonSpecific Ligand: 1 µM Yohimbine  
 K<sub>d</sub>: 7.8 nM \*  
 B<sub>max</sub>: 0.36 pmol/mg Protein\*
- 20      Specific Binding: 80% \*  
 Quantitation Method: Radioligand Binding  
 Significance Criteria: ≥ 50% of max stimulation or inhibition
- 25      **3. Adrenergic β** (Feve *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:5677-  
 5681).  
 Source: Wistar rat brain  
 Ligand: 0.25 nM <sup>3</sup>H Dihydroaplenolol  
 Vehicle: 0.4 % DMSO
- 30      Incubation Time/Temp: 20 minutes at 25 °C  
 Incubation Buffer: 50 mM Tris-HCl, pH 7.4  
 NonSpecific Ligand: 1µM S(-)-Propranolol  
 K<sub>d</sub>: 0.5 nM \*  
 B<sub>max</sub>: 0.083 pmol/mg Protein\*  
 Specific Binding: 85% \*

Quantitation Method: Radioligand Binding

Significance Criteria:  $\geq 50\%$  of max stimulation or inhibition

- 5     **4. Angiotensin AT<sub>2</sub>** (Whitebread *et al.*, 1991, *Biochem. Biophys. Res. Comm.* 181:1365-1371).

Source: Human recombinant Hela cells

Ligand: 0.025 nM <sup>125</sup>I CGP-42112A

Vehicle: 0.4 % DMSO

Incubation Time/Temp: 3 hours at 37 °C

- 10     Incubation Buffer: 50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 0.1% BSA, 1 mM EDTA,  
pH 7.4

NonSpecific Ligand: 10 µM [Sar<sup>1</sup>, Ile<sup>8</sup>]-Ang II

K<sub>d</sub>: 0.012 nM \*

B<sub>max</sub>: 2.9 pmol/mg Protein\*

- 15     Specific Binding: 90% \*

Quantitation Method: Radioligand Binding

Significance Criteria:  $\geq 50\%$  of max stimulation or inhibition

- 20     **5. Calcium Channel Type L, Dihydropyridine** (Ehlert *et al.*, 1982, *Life Sci.* 30:2191-2202).

Source: Wistar Rat cerebral cortex

Ligand: 0.1 nM <sup>3</sup>H Nitrendipine

Vehicle: 0.4 % DMSO

Incubation Time/Temp: 90 minutes at 25 °C

- 25     Incubation Buffer: 50 mM Tris-HCl, pH 7.7

NonSpecific Ligand: 1 µM Nitrendipine

K<sub>d</sub>: 0.18 nM \*

B<sub>max</sub>: 0.23 pmol/mg Protein\*

Specific Binding: 91% \*

- 30     Quantitation Method: Radioligand Binding

Significance Criteria:  $\geq 50\%$  of max stimulation or inhibition

- 6. Dopamine D<sub>2L</sub>** (Bunzo *et al.*, 1988, *Nature* 336:783-787).

Source: Human recombinant CHO cells

Ligand: 0.16 nM  $^3\text{H}$  Spiperone  
 Vehicle: 0.4 % DMSO  
 Incubation Time/Temp: 2 hours at 25  $^{\circ}\text{C}$   
 Incubation Buffer: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.4 mM ascorbic  
 5 acid, 0.001% BSA  
 NonSpecific Ligand: 10  $\mu\text{M}$  Haloperidol  
 $K_d$ : 0.08 nM \*  
 $B_{\text{max}}$ : 0.48 pmol/mg Protein\*  
 Specific Binding: 85% \*  
 10 Quantitation Method: Radioligand Binding  
 Significance Criteria:  $\geq 50\%$  of max stimulation or inhibition

**7. Endothelin  $\text{ET}_A$**  (Mihara *et al.*, 1994, *J. Pharmacol. Exp Ther.* 268:1122-  
 1127).

15 Source: Human recombinant CHO cells  
 Ligand: 0.03 nM  $^{125}\text{I}$  Endothelin  
 Vehicle: 0.4 % DMSO  
 Incubation Time/Temp: 2 hours at 37  $^{\circ}\text{C}$   
 Incubation Buffer: 50 mM Tris-HCl, pH 7.4, 0.5 mM  $\text{CaCl}_2$ , 0.1% bacitracin,  
 20 0.05% Tween-20, 1 mg/ml BSA  
 NonSpecific Ligand: 0.1  $\mu\text{M}$  Endothelin-1  
 $K_d$ : 0.048 nM \*  
 $B_{\text{max}}$ : 0.35 pmol/mg Protein\*  
 Specific Binding: 90% \*  
 25 Quantitation Method: Radioligand Binding  
 Significance Criteria:  $\geq 50\%$  of max stimulation or inhibition

**8. Histamine  $\text{H}_1$ , Central** (Hill *et al.*, 1978, *J. Neurochem.* 31:997-1004).

Source: Guinea pig cerebellum  
 30 Ligand: 1.75 nM  $^3\text{H}$  Pyrilamine  
 Vehicle: 0.4 % DMSO  
 Incubation Time/Temp: 60 minutes at 25  $^{\circ}\text{C}$   
 Incubation Buffer: 50 mM K-Na phosphate buffer pH 7.4 at 25 $^{\circ}\text{C}$   
 NonSpecific Ligand: 1  $\mu\text{M}$  Pyrilamine

K<sub>d</sub>: 0.23 nM \*  
B<sub>max</sub>: 0.198 pmol/mg Protein\*  
Specific Binding: 90% \*  
Quantitation Method: Radioligand Binding  
5 Significance Criteria: ≥ 50% of max stimulation or inhibition

**9. Muscarinic non-selective, Central** (Luthin and Wolfe, 1984, *J. Pharmacol. Exp. Ther.* 228:648-655).

Source: Wistar rat cerebral cortex  
10 Ligand: 0.29 nM <sup>3</sup>H Quinuclidinyl benzilate  
Vehicle: 0.4 % DMSO  
Incubation Time/Temp: 60 minutes at 25 °C  
Incubation Buffer: 50 mM Na-K Phosphate, pH 7.4  
NonSpecific Ligand: 0.1 μM Atropine  
15 K<sub>d</sub>: 0.068 nM \*  
B<sub>max</sub>: 1.4 pmol/mg Protein\*  
Specific Binding: 97% \*  
Quantitation Method: Radioligand Binding  
Significance Criteria: ≥ 50% of max stimulation or inhibition

20

**10. Serotonin 5-HT<sub>1</sub>, non-selective** (Middlemiss, 1984, *Eur. J. Pharmacol.* 101:289-293).

Source: Wistar rat cerebral cortex  
Ligand: 2 nM <sup>3</sup>H Serotonin (5-HT) Trifluoroacetate  
25 Vehicle: 0.4 % DMSO  
Incubation Time/Temp: 10 minutes at 25 °C  
Incubation Buffer: 50 mM Tris-HCl, 0.1% ascorbic acid, 10 μM pargyline, 4 mM CaCl<sub>2</sub>, pH 7.6  
NonSpecific Ligand: 10 μM 5-HT (Serotonin)  
30 K<sub>d</sub>: 0.61 nM \*  
B<sub>max</sub>: 0.58 pmol/mg Protein\*  
Specific Binding: 80% \*  
Quantitation Method: Radioligand Binding  
Significance Criteria: ≥ 50% of max stimulation or inhibition

**\* Historical Values**

Finally, it should be noted that there are alternative ways of implementing  
5 both the present invention. Accordingly, the present embodiments are to be  
considered as illustrative and not restrictive, and the invention is not to be limited to  
the details given herein, but may be modified within the scope and equivalents of the  
appended claims.

All publications and patents cited herein incorporated by reference in their  
10 entirety.